Abstract:DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies.DIAGNOSIS: The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE) namely CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions) features felt related to the plasma cell disorder, bone marrow clonal plasmacytosis ≥60%, serum involved/uninvolved free light chain (FLC) ratio ≥100 (provided involved FLC is ≥100 mg/L), or >1 focal lesion on magnetic resonance imaging (MRI).RISK STRATIFICATION: The presence of del(17p), t(4;14), t(14;16), t(14;20), gain 1q, or p53 mutation is considered high-risk multiple myeloma. Presence of any two high risk factors is considered double-hit myeloma; three or more high risk factors is triple-hit myeloma.RISK-ADAPTED INITIAL THERAPY: In transplant eligible patients, induction therapy consists of bortezomib, lenalidomide, dexamethasone (VRd) given for approximately 3-4 cycles followed by autologous stem cell transplantation (ASCT). In high-risk patients, daratumumab, bortezomib, lenalidomide, dexamethasone (Dara-VRd) is an alternative to VRd. Selected standard risk patients can get additional cycles of induction, and delay transplant until first relapse. Patients not candidates for transplant are typically treated with VRd for approximately 8-12 cycles followed by lenalidomide; alternatively these patients can be treated with daratumumab, lenalidomide, dexamethasone (DRd).MAINTENANCE THERAPY: After ASCT, standard risk patients need lenalidomide maintenance, while bortezomib-based maintenance is needed for patients with high-risk myeloma.MANAGEMENT OF REFRACTORY DISEASE: Most patients require a triplet regimen at relapse, with the choice of regimen varying with each successive relapse.

An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities

Multiple myeloma, immunotherapy and minimal residual disease

Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management

Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics

Current approaches to management of newly diagnosed multiple myeloma

Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer

Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)

Multiple myeloma in the marrow: pathogenesis and treatments

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management

Multiple myeloma: signaling pathways and targeted therapy

New diagnostic strategy for multiple myeloma: A review

Pros and cons for fluorescent in situ hybridization, karyotyping and next generation sequencing for diagnosis and follow-up of multiple myeloma

Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

Analysis of Multiple Myeloma Drug Efficacy

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions

Smoldering multiple myeloma current treatment algorithms

Practical guidance for new multiple myeloma treatment regimens: A nursing perspective

Recent Advances in The Definition of the Molecular Alterations Occurring in Multiple Myeloma